Is NCT02920398 results overdue?

Yes — results are overdue. Primary completion was 2017-04-07; the FDAAA-801 reporting deadline (2018-04-07) passed 2997 days ago and no results are posted on ClinicalTrials.gov.

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

NCT ID	NCT02920398 ↗
Sponsor	Novo Nordisk A/S (INDUSTRY)
Public issuer	NOVO NORDISK A S — NVO (CIK 0000353278) best-effort name match, 95% conf — verify on EDGAR ↗
Phase	PHASE1
Status	COMPLETED
Primary completion	2017-04-07 (ACTUAL)
Reporting deadline	2018-04-07 (completion + 365d)
Days overdue	2997
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `87822ff289af9538…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02920398. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.